S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
Log in
NASDAQ:RMTI

Rockwell Medical Competitors

$1.00
-0.03 (-2.93 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.97
Now: $1.00
$1.06
50-Day Range
$0.84
MA: $0.98
$1.11
52-Week Range
$0.83
Now: $1.00
$3.85
Volume1.23 million shs
Average Volume1.22 million shs
Market Capitalization$93.11 million
P/E RatioN/A
Dividend YieldN/A
Beta1.25

Competitors

Rockwell Medical (NASDAQ:RMTI) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying RMTI stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Rockwell Medical, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

Abbott Laboratories (NYSE:ABT) and Rockwell Medical (NASDAQ:RMTI) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Abbott Laboratories and Rockwell Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories141302.67
Rockwell Medical00103.00

Abbott Laboratories presently has a consensus target price of $115.3750, suggesting a potential upside of 8.42%. Rockwell Medical has a consensus target price of $9.00, suggesting a potential upside of 804.52%. Given Rockwell Medical's stronger consensus rating and higher probable upside, analysts clearly believe Rockwell Medical is more favorable than Abbott Laboratories.

Insider and Institutional Ownership

63.9% of Abbott Laboratories shares are held by institutional investors. Comparatively, 21.1% of Rockwell Medical shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by insiders. Comparatively, 4.7% of Rockwell Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Abbott Laboratories and Rockwell Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories10.50%18.19%8.29%
Rockwell Medical-47.94%-146.49%-55.15%

Volatility and Risk

Abbott Laboratories has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.

Valuation & Earnings

This table compares Abbott Laboratories and Rockwell Medical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion5.91$3.69 billion$3.2432.84
Rockwell Medical$61.30 million1.52$-34,130,000.00($0.56)-1.78

Abbott Laboratories has higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

Abbott Laboratories beats Rockwell Medical on 10 of the 14 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Rockwell Medical (NASDAQ:RMTI) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Valuation & Earnings

This table compares Medtronic and Rockwell Medical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$28.91 billion5.27$4.79 billion$4.5924.69
Rockwell Medical$61.30 million1.52$-34,130,000.00($0.56)-1.78

Medtronic has higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Medtronic and Rockwell Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic132012.84
Rockwell Medical00103.00

Medtronic presently has a consensus target price of $122.00, suggesting a potential upside of 7.67%. Rockwell Medical has a consensus target price of $9.00, suggesting a potential upside of 804.52%. Given Rockwell Medical's stronger consensus rating and higher probable upside, analysts clearly believe Rockwell Medical is more favorable than Medtronic.

Insider and Institutional Ownership

79.9% of Medtronic shares are held by institutional investors. Comparatively, 21.1% of Rockwell Medical shares are held by institutional investors. 0.5% of Medtronic shares are held by insiders. Comparatively, 4.7% of Rockwell Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Medtronic and Rockwell Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic15.80%10.47%5.80%
Rockwell Medical-47.94%-146.49%-55.15%

Volatility and Risk

Medtronic has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.

Summary

Medtronic beats Rockwell Medical on 11 of the 15 factors compared between the two stocks.

Stryker (NYSE:SYK) and Rockwell Medical (NASDAQ:RMTI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.

Earnings and Valuation

This table compares Stryker and Rockwell Medical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion5.90$2.08 billion$8.2628.30
Rockwell Medical$61.30 million1.52$-34,130,000.00($0.56)-1.78

Stryker has higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Stryker and Rockwell Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker291512.56
Rockwell Medical00103.00

Stryker presently has a consensus target price of $221.44, suggesting a potential downside of 5.25%. Rockwell Medical has a consensus target price of $9.00, suggesting a potential upside of 804.52%. Given Rockwell Medical's stronger consensus rating and higher probable upside, analysts plainly believe Rockwell Medical is more favorable than Stryker.

Insider & Institutional Ownership

71.0% of Stryker shares are held by institutional investors. Comparatively, 21.1% of Rockwell Medical shares are held by institutional investors. 6.8% of Stryker shares are held by insiders. Comparatively, 4.7% of Rockwell Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Stryker and Rockwell Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker11.38%20.53%8.89%
Rockwell Medical-47.94%-146.49%-55.15%

Risk & Volatility

Stryker has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.

Summary

Stryker beats Rockwell Medical on 12 of the 15 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Rockwell Medical (NASDAQ:RMTI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.

Earnings and Valuation

This table compares Intuitive Surgical and Rockwell Medical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion19.07$1.38 billion$9.9573.00
Rockwell Medical$61.30 million1.52$-34,130,000.00($0.56)-1.78

Intuitive Surgical has higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Intuitive Surgical and Rockwell Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical371202.41
Rockwell Medical00103.00

Intuitive Surgical presently has a consensus target price of $718.2778, suggesting a potential downside of 1.11%. Rockwell Medical has a consensus target price of $9.00, suggesting a potential upside of 804.52%. Given Rockwell Medical's stronger consensus rating and higher probable upside, analysts plainly believe Rockwell Medical is more favorable than Intuitive Surgical.

Insider & Institutional Ownership

86.9% of Intuitive Surgical shares are held by institutional investors. Comparatively, 21.1% of Rockwell Medical shares are held by institutional investors. 1.6% of Intuitive Surgical shares are held by insiders. Comparatively, 4.7% of Rockwell Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Intuitive Surgical and Rockwell Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical24.45%12.08%10.44%
Rockwell Medical-47.94%-146.49%-55.15%

Risk & Volatility

Intuitive Surgical has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.

Summary

Intuitive Surgical beats Rockwell Medical on 10 of the 14 factors compared between the two stocks.

Becton, Dickinson and (NYSE:BDX) and Rockwell Medical (NASDAQ:RMTI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.

Earnings and Valuation

This table compares Becton, Dickinson and and Rockwell Medical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and$17.12 billion3.85$874 million$10.2022.30
Rockwell Medical$61.30 million1.52$-34,130,000.00($0.56)-1.78

Becton, Dickinson and has higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Becton, Dickinson and and Rockwell Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Becton, Dickinson and07712.60
Rockwell Medical00103.00

Becton, Dickinson and presently has a consensus target price of $280.2857, suggesting a potential upside of 23.22%. Rockwell Medical has a consensus target price of $9.00, suggesting a potential upside of 804.52%. Given Rockwell Medical's stronger consensus rating and higher probable upside, analysts plainly believe Rockwell Medical is more favorable than Becton, Dickinson and.

Profitability

This table compares Becton, Dickinson and and Rockwell Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Becton, Dickinson and5.11%13.30%5.60%
Rockwell Medical-47.94%-146.49%-55.15%

Insider & Institutional Ownership

74.4% of Becton, Dickinson and shares are held by institutional investors. Comparatively, 21.1% of Rockwell Medical shares are held by institutional investors. 0.1% of Becton, Dickinson and shares are held by insiders. Comparatively, 4.7% of Rockwell Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Becton, Dickinson and has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.

Summary

Becton, Dickinson and beats Rockwell Medical on 11 of the 15 factors compared between the two stocks.

Rockwell Medical (NASDAQ:RMTI) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.

Risk & Volatility

Rockwell Medical has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Rockwell Medical and Edwards Lifesciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rockwell Medical00103.00
Edwards Lifesciences251302.55

Rockwell Medical presently has a consensus target price of $9.00, indicating a potential upside of 804.52%. Edwards Lifesciences has a consensus target price of $87.7222, indicating a potential upside of 4.17%. Given Rockwell Medical's stronger consensus rating and higher probable upside, analysts plainly believe Rockwell Medical is more favorable than Edwards Lifesciences.

Profitability

This table compares Rockwell Medical and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rockwell Medical-47.94%-146.49%-55.15%
Edwards Lifesciences18.18%29.00%18.10%

Earnings & Valuation

This table compares Rockwell Medical and Edwards Lifesciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rockwell Medical$61.30 million1.52$-34,130,000.00($0.56)-1.78
Edwards Lifesciences$4.35 billion12.07$1.05 billion$1.8645.27

Edwards Lifesciences has higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

21.1% of Rockwell Medical shares are owned by institutional investors. Comparatively, 79.7% of Edwards Lifesciences shares are owned by institutional investors. 4.7% of Rockwell Medical shares are owned by insiders. Comparatively, 1.5% of Edwards Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Edwards Lifesciences beats Rockwell Medical on 10 of the 14 factors compared between the two stocks.


Rockwell Medical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.2$106.41-1.1%$188.60 billion$31.90 billion56.30
Medtronic logo
MDT
Medtronic
2.7$113.31-0.7%$152.31 billion$28.91 billion34.65Earnings Announcement
Analyst Report
Analyst Revision
Heavy News Reporting
Stryker logo
SYK
Stryker
2.0$233.72-2.8%$87.83 billion$14.88 billion55.52Insider Selling
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$726.37-0.2%$85.39 billion$4.48 billion82.73
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$227.47-0.8%$65.94 billion$17.12 billion83.32Dividend Increase
Insider Selling
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$84.21-1.7%$52.48 billion$4.35 billion67.37
Boston Scientific logo
BSX
Boston Scientific
2.4$33.55-0.7%$48.04 billion$10.74 billion12.85
Baxter International logo
BAX
Baxter International
2.3$75.39-0.8%$38.51 billion$11.36 billion42.84
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$446.48-0.1%$38.08 billion$2.41 billion77.78
DexCom logo
DXCM
DexCom
2.1$312.55-0.2%$30.01 billion$1.48 billion129.15Insider Selling
ResMed logo
RMD
ResMed
1.7$206.03-0.2%$29.86 billion$2.96 billion48.25Insider Selling
Hologic logo
HOLX
Hologic
1.9$68.23-0.8%$17.54 billion$3.37 billion16.25Analyst Downgrade
Analyst Revision
Teleflex logo
TFX
Teleflex
1.8$373.66-2.1%$17.40 billion$2.60 billion36.78
Insulet logo
PODD
Insulet
1.3$248.86-1.9%$16.41 billion$738.20 million888.82
STERIS logo
STE
STERIS
1.9$189.29-0.7%$16.15 billion$3.03 billion39.35Ex-Dividend
Varian Medical Systems logo
VAR
Varian Medical Systems
1.4$174.11-0.0%$15.83 billion$3.23 billion56.71Analyst Downgrade
Insider Selling
Heavy News Reporting
Masimo logo
MASI
Masimo
1.6$245.41-0.6%$13.51 billion$937.84 million63.74
Abiomed logo
ABMD
Abiomed
1.5$263.82-0.7%$11.92 billion$840.88 million57.98
Hill-Rom logo
HRC
Hill-Rom
1.9$95.47-1.6%$6.38 billion$2.91 billion30.80Unusual Options Activity
Globus Medical logo
GMED
Globus Medical
1.5$59.80-0.1%$5.90 billion$785.37 million65.00
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$54.40-2.4%$4.58 billion$1.52 billion81.19
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$29.98-0.0%$3.90 billion$920.90 million-28.28
CONMED logo
CNMD
CONMED
1.5$104.44-2.2%$2.99 billion$955.10 million109.94Insider Selling
NuVasive logo
NUVA
NuVasive
1.8$47.56-1.0%$2.44 billion$1.17 billion-216.18
Integer logo
ITGR
Integer
2.2$72.42-1.8%$2.38 billion$1.26 billion32.92Analyst Upgrade
AtriCure logo
ATRC
AtriCure
1.5$43.63-0.8%$1.96 billion$230.81 million-37.94
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$35.29-0.4%$1.42 billion$236.54 million-53.47Analyst Downgrade
Alphatec logo
ATEC
Alphatec
1.2$10.95-3.5%$858.75 million$113.43 million-9.95High Trading Volume
CryoLife logo
CRY
CryoLife
2.1$21.09-2.5%$819.49 million$276.22 million-55.50
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$38.14-1.4%$737.40 million$459.95 million31.78
AngioDynamics logo
ANGO
AngioDynamics
1.5$14.38-9.4%$545.76 million$264.16 million-3.25Analyst Upgrade
High Trading Volume
Heavy News Reporting
Surmodics logo
SRDX
Surmodics
1.5$38.93-1.5%$529.68 million$100.08 million69.52
Accuray logo
ARAY
Accuray
2.0$4.36-4.1%$397.96 million$382.93 million31.14Unusual Options Activity
Invacare logo
IVC
Invacare
1.4$8.76-4.0%$301.50 million$927.96 million-7.12
This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.